J&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated ...

Tabrecta approved in Europe Meanwhile, Novartis also has good news in its targeted oncology business on the other side of the Atlantic, as the European Commission has approved its Incyte-partnered ...

Several c-Met-targeting drugs have already reached the market – including Novartis’ Tabrecta (capmatinib), Merck KGaA’s Tepmetko (tepotinib), and Hutchmed’s Orpathys (savolitinib ...